《大行报告》瑞信降巨星医疗控股(02393.HK)评级至「中性」 目标价下调至1.2元
瑞信发表研究报告,指巨星医疗控股(02393.HK)去年下半年疫後复苏慢过预期,收入按年跌4.3%至25.05亿元人民币,与行业整体良好复苏趋势背驰。该行料其今年复苏步伐改善,但仅与2019年增长持平,该行料其今年医用消耗品及成像印刷销售按年分别升20%及30%。
报告称,巨星医疗有2亿美元高级债今年9月到期引发关注,於去年底止公司现金结余仅5.72亿元人民币,去年底止杠杆比率0.86。瑞信下调其目标价由1.5元降至1.2元,下调今明两年每股盈测分别33%及24%,考虑流动性引起关注,投资评级由「跑赢大市」降至「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.